Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

Survivorship & Monitoring: Life After Treatment

At a Glance

After finishing treatment for anaplastic large cell lymphoma (ALCL), survivorship involves close monitoring for the first two years. Key steps include managing scan anxiety, monitoring for long-term side effects like neuropathy or heart issues, and knowing the warning signs of relapse.

Achieving remission is a major milestone, but it also marks the beginning of a new phase: survivorship. This stage is focused on monitoring for any signs of the cancer returning and managing the long-term effects of the powerful treatments that saved your life [1][2].

Your Surveillance Roadmap

Monitoring for Anaplastic Large Cell Lymphoma (ALCL) is most intensive in the first two years after treatment, as this is the window when a relapse is most likely to occur [3].

Typical Follow-Up Schedule

While every clinic is different, a standard surveillance plan often includes:

  • Years 1–2: Clinic visits and physical exams every 3 to 6 months [4]. Imaging (such as PET/CT scans) may be done periodically, though many doctors now prefer to use scans only if symptoms appear [5].
  • Years 3–5: Visits typically move to every 6 to 12 months [4].
  • After 5 Years: You may transition to an annual “survivorship clinic” that focuses on long-term health and late effects of treatment [6][7].

Managing “Scanxiety”

It is completely normal to feel a spike in distress, often called scanxiety, in the days leading up to a follow-up scan and while waiting for results [8][9].

  • Why it Happens: The waiting period can trigger fears of the cancer returning, even if you feel perfectly healthy [10][11]. Please know that it is completely normal to experience this anxiety for years after being cured; you are not alone in feeling this way.
  • Strategies to Cope: Ask your doctor if results can be shared via a phone call as soon as they are ready to minimize waiting [9]. Many patients find that exercise, relaxation training, or cognitive-behavioral support can help manage these waves of anxiety [12][13].

Long-Term Side Effects to Watch For

Modern treatments like brentuximab vedotin (BV) and ALK inhibitors are effective but can leave “fingerprints” on your health [14][15].

Peripheral Neuropathy

A common side effect of BV is peripheral neuropathy—damage to the nerves that causes tingling, numbness, or “pins and needles” in the hands and feet [16][17].

  • The Good News: For many patients, this neuropathy improves or resolves entirely after treatment ends [18][19].
  • Self-Monitoring: Tell your doctor if you have trouble with fine motor skills (like buttoning a shirt) or if you feel unsteady on your feet [19].

Heart Health

If your treatment included “anthracyclines” (like doxorubicin), your heart requires lifelong monitoring [5].

  • Current Guidelines: The Children’s Oncology Group (COG) provides specific schedules for heart scans (echocardiograms) based on the total dose of medicine you received [5][20].

Actionable Self-Monitoring Tips

You are the expert on your own body (or your child’s). Contact your care team if you notice:

  1. New Lumps: Any new, painless swelling in the neck, armpits, or groin [21].
  2. Persistent “B-Symptoms”: The return of drenching night sweats, unexplained fevers, or rapid weight loss [22].
  3. Skin Changes: New nodules or sores that do not heal [23].
  4. BIA-ALCL Specifics: If you have breast implants, watch for sudden, new swelling (fluid) or a mass around the implant [24][25].

Having a formal Survivorship Care Plan—a document summarizing your diagnosis, treatment dates, and specific drugs—is one of the best ways to ensure you get the right monitoring for the rest of your life [2][6].

Return to Home

Common questions in this guide

How often do I need follow-up appointments after ALCL treatment?
During the first two years, you will typically have clinic visits and physical exams every 3 to 6 months. Between years three and five, visits usually transition to every 6 to 12 months.
Will the numbness in my hands and feet from brentuximab go away?
Peripheral neuropathy, which causes tingling or numbness, is a common side effect of brentuximab vedotin. For many patients, this nerve issue improves or completely resolves after treatment ends.
What are the signs that ALCL might be returning?
You should contact your doctor if you notice new painless lumps in your neck, armpits, or groin. Other warning signs include the return of drenching night sweats, unexplained fevers, rapid weight loss, or skin sores that do not heal.
Why do I need heart scans after finishing lymphoma treatment?
If your treatment included anthracycline chemotherapy drugs like doxorubicin, it can have long-term effects on your heart. Your doctor will use echocardiograms to monitor your heart health based on the total dose of medication you received.
What is a Survivorship Care Plan?
A Survivorship Care Plan is a formal document summarizing your exact diagnosis, treatment dates, and the specific drugs you received. It serves as a personalized roadmap to ensure you get the right health monitoring for the rest of your life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific schedule for follow-up visits and imaging over the next two years?
  2. 2.Can you provide a formal 'Survivorship Care Plan' that lists my cumulative doses of drugs like doxorubicin?
  3. 3.Based on my treatment, do I still need routine heart scans (echocardiograms), and how often?
  4. 4.How long should I expect the tingling or numbness from brentuximab (neuropathy) to last?
  5. 5.Who should I contact immediately if I find a new lump or notice unexplained fevers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?

    Milunović V

    Medicina (Kaunas, Lithuania) 2024; (60(2)) doi:10.3390/medicina60020344.

    PMID: 38399631
  2. 2

    A Meta-Ethnography of the Experiences of Adults with Lymphoma During Acute and Chronic Survivorship.

    Vena JA, Copel LC

    Seminars in oncology nursing 2021; (37(2)):151142 doi:10.1016/j.soncn.2021.151142.

    PMID: 33773881
  3. 3

    [ALK-positive anaplastic large cell lymphoma of paranasal sinuses: two cases report and literature review].

    Abramov DS, Fedorova AS, Tuzova EA, et al.

    Arkhiv patologii 2024; (86(4)):42-47 doi:10.17116/patol20248604142.

    PMID: 39073541
  4. 4

    Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda.

    Valcarcel B, Savage KJ, Link BK, et al.

    JCO oncology practice 2025; (21(6)):801-812 doi:10.1200/OP.24.00364.

    PMID: 39642333
  5. 5

    The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.

    DeVine A, Landier W, Hudson MM, et al.

    JAMA oncology 2025; (11(5)):544-553 doi:10.1001/jamaoncol.2024.6812.

    PMID: 39976936
  6. 6

    Specialized survivor clinic attendance increases adherence to cardiomyopathy screening guidelines in adult survivors of childhood cancer.

    Marr KC, Agha M, Sutradhar R, et al.

    Journal of cancer survivorship : research and practice 2017; (11(5)):614-623 doi:10.1007/s11764-017-0634-z.

    PMID: 28785871
  7. 7

    Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study.

    Yan AP, Chen Y, Henderson TO, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(15)):1711-1722 doi:10.1200/JCO.19.01825.

    PMID: 32142393
  8. 8

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  9. 9

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  10. 10

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  11. 11

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  12. 12

    Relaxation versus exercise for improved quality of life in lymphoma survivors-a randomised controlled trial.

    Hathiramani S, Pettengell R, Moir H, Younis A

    Journal of cancer survivorship : research and practice 2021; (15(3)):470-480 doi:10.1007/s11764-020-00941-4.

    PMID: 32986231
  13. 13

    Cognitive behavioral stress management effects on cancer-related distress and neuroendocrine signaling in breast cancer: differential effects by neighborhood disadvantage.

    Ream M, Plotke R, Taub CJ, et al.

    Breast cancer research and treatment 2025; (211(1)):161-172 doi:10.1007/s10549-025-07631-8.

    PMID: 39966311
  14. 14

    Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system.

    Chen Y, Ren X, Dai Y, Wang Y

    Scientific reports 2024; (14(1)):21386 doi:10.1038/s41598-024-71977-0.

    PMID: 39271716
  15. 15

    Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.

    Caddeo G, Tecchio C, Chinello M, et al.

    Clinical hematology international 2023; (5(2-3)):130-138 doi:10.1007/s44228-023-00038-6.

    PMID: 37072555
  16. 16

    Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.

    Matthys A, Bardel B, Le Bras F, et al.

    European journal of neurology 2024; (31(7)):e16285 doi:10.1111/ene.16285.

    PMID: 38511878
  17. 17

    Peripheral neuropathy in hematologic malignancies - Past, present and future.

    Li T, Timmins HC, Lazarus HM, Park SB

    Blood reviews 2020; (43()):100653 doi:10.1016/j.blre.2020.100653.

    PMID: 31983507
  18. 18

    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

    Pro B, Advani R, Brice P, et al.

    Blood 2017; (130(25)):2709-2717 doi:10.1182/blood-2017-05-780049.

    PMID: 28974506
  19. 19

    Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy.

    Velasco R, Domingo-Domenech E, Sureda A

    Cancers 2021; (13(23)) doi:10.3390/cancers13236125.

    PMID: 34885234
  20. 20

    Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks.

    Taghdiri A

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2024; (76(1)):71 doi:10.1186/s43044-024-00506-1.

    PMID: 38849680
  21. 21

    Primary Gingival Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma in a Young Boy.

    Lutz CM, Bruneau J, Molina TJ, Ejeil AL

    Cureus 2025; (17(8)):e89217 doi:10.7759/cureus.89217.

    PMID: 40895696
  22. 22

    Skin involvement as the first manifestation of breast implant-associated anaplastic large cell lymphoma.

    Alcalá R, Llombart B, Lavernia J, et al.

    Journal of cutaneous pathology 2016; (43(7)):602-608 doi:10.1111/cup.12697.

    PMID: 26956670
  23. 23

    Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report.

    Uzuncakmak TK, Akdeniz N, Karadag AS, et al.

    Dermatology practical & conceptual 2017; (7(1)):59-61 doi:10.5826/dpc.0701a12.

    PMID: 28243498
  24. 24

    Achieving Reliable Diagnosis in Late Breast Implant Seromas: From Reactive to Anaplastic Large Cell Lymphoma.

    Di Napoli A

    Plastic and reconstructive surgery 2019; (143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma)):15S-22S doi:10.1097/PRS.0000000000005565.

    PMID: 30817552
  25. 25

    A practical cytological approach to the diagnosis of breast-implant associated anaplastic large cell lymphoma.

    Barbé E, de Boer M, de Jong D

    Cytopathology : official journal of the British Society for Clinical Cytology 2019; (30(4)):363-369 doi:10.1111/cyt.12678.

    PMID: 30628128

This page provides educational information about ALCL survivorship and monitoring. It does not replace professional medical advice, and you should always discuss your specific follow-up plan with your oncology team.

Get notified when new evidence is published on Anaplastic large cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.